Table 3.

Multivariate analysis with covariate considerations

HR (95% CI)PP (unadjusted)
Relapse incidence    
 UCB vs MUD 0.59 (0.31-1.1) .84 .12 
 MSD vs MUD 0.71 (0.34-1.5) 1  
 MSD vs UCB 1.2 (0.59-2.5) 1 .59 
 MSD vs dUCB 0.91 (0.4-2) 1 .8 
  Chemo-based vs TBI-based 0.77 (0.45-1.3)  .36 
  Age at HCT (spline 1) 0.86 (0.76-0.97)  .015 
  Age at HCT (spline 2) 1.2 (1-1.4)  .03 
LFS    
 UCB vs MUD 1 (0.62-1.7) 1 .9 
 MSD vs MUD 0.83 (0.45-1.4) 1 .48 
 MSD vs UCB 0.77 (0.45-1.3) 1 .37 
 MSD vs dUCB 0.56 (0.3-1) .406 .058 
  Age at HCT (spline 1) 0.88 (0.8-0.96)  .0054 
  Age at HCT (spline 2) 1.1 (1-1.3)  .012 
  BuCy-like vs BuFlu 0.43 (0.17-1.1)  077 
  BuCy-like vs BuMel-like 0.91 (0.5-1.7)  .77 
  BuCy-like vs Other 0.77 (0.4-1.4)  .39 
  BuCy-like vs TBI-based 1 (0.56-1.8)  .99 
Nonrelapse mortality    
 UCB vs MUD 1.6 (0.67-3.8) 1 .28 
 MSD vs MUD 1.1 (0.37-3.1) 1 .89 
 MSD vs UCB 0.67 (0.28-1.6) 1 .37 
 MSD vs dUCB 0.42 (0.16-1.1) .497 .071 
  Chemo-based vs TBI-based 1.2 (0.62-2.2)  .59 
  Age at HCT (spline 1) 0.94 (0.81-1.1)  .37 
  Age at HCT (spline 2) 1.1 (0.9-1.3)  .49 
OS    
 UCB vs MUD 1 (0.59-1.8) 1 .92 
 MSD vs MUD 0.67 (0.36-1.3) 1 .22 
 MSD vs UCB 0.67 (0.36-1.2) 1 .16 
 MSD vs dUCB 0.43 (0.23-0.83) .091 .013 
  Age at HCT (spline 1) 0.91 (0.83-1)  .053 
  Age at HCT (spline 2) 1.1 (1-1.2)  .061 
  BuCy-like vs BuFlu 0.34 (0.13-0.91)  .029 
  BuCy-like vs BuMel-like 0.77 (0.38-1.4)  .38 
  BuCy-like vs Other 0.59 (0.3-1.2)  .13 
  BuCy-like vs TBI-based 0.91 (0.5-1.8)  .82 
Incidence of aGVHD grades II-IV    
 UCB vs MUD 1 (0.56-1.8) 1 .98 
 MSD vs MUD 0.59 (0.3-1.2) .98 .14 
 MSD vs UCB 0.62 (0.3-1.2) 1 .15 
 MSD vs dUCB 0.56 (0.29-1.1) .7 .1 
  Chemo-based vs TBI-based 0.56 (0.36-0.83)  .0046 
  Age at HCT (spline 1) 0.97 (0.89-1.1)  .53 
  Age at HCT (spline 2) 1 (0.9-1.1)  .93 
  CSA/MMF vs CSA/Mtx 2 (1.1-3.7)  .017 
  CSA/MMF vs CSA/steroids 1.4 (0.77-2.4)  .31 
  No serotherapy vs ATG 1.3 (0.83-2)  .3 
  No serotherapy vs Campath 0.91 (0.43-1.8)  .73 
Incidence of aGVHD grades III-IV    
 UCB vs MUD 4.2 (1-18) .357 .051 
 MSD vs MUD 1.4 (0.33-5.9) 1 .64 
 MSD vs UCB 0.33 (0.091-1.2) .658 .094 
 MSD vs dUCB 0.43 (0.12-1.6) 1 .22 
  Chemo-based vs TBI-based 1 (0.45-2)  .9 
  Age at HCT (spline 1) 0.91 (0.79-1.1)  .21 
  Age at HCT (spline 2) 1.1 (0.93-1.3)  .27 
  CSA/MMF vs CSA/Mtx 1.1 (0.31-3.8)  .88 
  CSA/MMF vs CSA/steroids 2 (0.83-5)  .13 
  No serotherapy vs ATG 1.1 (0.53-2.3)  .8 
  No serotherapy vs Campath 0.91 (0.19-4.2)  .88 
Incidence of cGVHD    
 UCB vs MUD 0.3 (0.14-0.67) .0217 .0031 
 MSD vs MUD 0.5 (0.21-1.1) .672 .096 
 MSD vs UCB 1.6 (0.62-4.2) 1 .3 
 MSD vs dUCB 1.5 (0.59-3.8) 1 .41 
  Chemo-based vs TBI-based 0.43 (0.24-0.83)  .0076 
  Age at HCT (spline 1) 1.1 (0.93-1.2)  .4 
  Age at HCT (spline 2) 0.9 (0.78-1)  .17 
  CSA/MMF vs CSA/Mtx 2.1 (1.1-4.3)  .032 
  CSA/MMF vs CSA/steroids 3.6 (0.83-16)  .093 
  No serotherapy vs ATG 1.1 (0.53-2.5)  .75 
  No serotherapy vs Campath 1 (0.42-2.3)  .94 
cGVHD-LFS    
 UCB vs MUD 0.56 (0.34-1) .033 .033 
 MSD vs MUD 0.67 (0.4-1) .073 .073 
 MSD vs UCB 1.1 (0.67-2) .65 .65 
 MSD vs dUCB 1 (0.56-1.8) .95 .95 
  Chemo-based vs TBI-based 0.83 (0.59-1.2)  .37 
  Age at HCT (spline 1) 0.95 (0.88-1)  .16 
  Age at HCT (spline 2) 1 (0.95-1.1)  .41 
  CSA/MMF vs CSA/Mtx 1.7 (1.1-2.8)  .025 
  CSA/MMF vs CSA/steroids 1.5 (0.91-2.6)  .14 
HR (95% CI)PP (unadjusted)
Relapse incidence    
 UCB vs MUD 0.59 (0.31-1.1) .84 .12 
 MSD vs MUD 0.71 (0.34-1.5) 1  
 MSD vs UCB 1.2 (0.59-2.5) 1 .59 
 MSD vs dUCB 0.91 (0.4-2) 1 .8 
  Chemo-based vs TBI-based 0.77 (0.45-1.3)  .36 
  Age at HCT (spline 1) 0.86 (0.76-0.97)  .015 
  Age at HCT (spline 2) 1.2 (1-1.4)  .03 
LFS    
 UCB vs MUD 1 (0.62-1.7) 1 .9 
 MSD vs MUD 0.83 (0.45-1.4) 1 .48 
 MSD vs UCB 0.77 (0.45-1.3) 1 .37 
 MSD vs dUCB 0.56 (0.3-1) .406 .058 
  Age at HCT (spline 1) 0.88 (0.8-0.96)  .0054 
  Age at HCT (spline 2) 1.1 (1-1.3)  .012 
  BuCy-like vs BuFlu 0.43 (0.17-1.1)  077 
  BuCy-like vs BuMel-like 0.91 (0.5-1.7)  .77 
  BuCy-like vs Other 0.77 (0.4-1.4)  .39 
  BuCy-like vs TBI-based 1 (0.56-1.8)  .99 
Nonrelapse mortality    
 UCB vs MUD 1.6 (0.67-3.8) 1 .28 
 MSD vs MUD 1.1 (0.37-3.1) 1 .89 
 MSD vs UCB 0.67 (0.28-1.6) 1 .37 
 MSD vs dUCB 0.42 (0.16-1.1) .497 .071 
  Chemo-based vs TBI-based 1.2 (0.62-2.2)  .59 
  Age at HCT (spline 1) 0.94 (0.81-1.1)  .37 
  Age at HCT (spline 2) 1.1 (0.9-1.3)  .49 
OS    
 UCB vs MUD 1 (0.59-1.8) 1 .92 
 MSD vs MUD 0.67 (0.36-1.3) 1 .22 
 MSD vs UCB 0.67 (0.36-1.2) 1 .16 
 MSD vs dUCB 0.43 (0.23-0.83) .091 .013 
  Age at HCT (spline 1) 0.91 (0.83-1)  .053 
  Age at HCT (spline 2) 1.1 (1-1.2)  .061 
  BuCy-like vs BuFlu 0.34 (0.13-0.91)  .029 
  BuCy-like vs BuMel-like 0.77 (0.38-1.4)  .38 
  BuCy-like vs Other 0.59 (0.3-1.2)  .13 
  BuCy-like vs TBI-based 0.91 (0.5-1.8)  .82 
Incidence of aGVHD grades II-IV    
 UCB vs MUD 1 (0.56-1.8) 1 .98 
 MSD vs MUD 0.59 (0.3-1.2) .98 .14 
 MSD vs UCB 0.62 (0.3-1.2) 1 .15 
 MSD vs dUCB 0.56 (0.29-1.1) .7 .1 
  Chemo-based vs TBI-based 0.56 (0.36-0.83)  .0046 
  Age at HCT (spline 1) 0.97 (0.89-1.1)  .53 
  Age at HCT (spline 2) 1 (0.9-1.1)  .93 
  CSA/MMF vs CSA/Mtx 2 (1.1-3.7)  .017 
  CSA/MMF vs CSA/steroids 1.4 (0.77-2.4)  .31 
  No serotherapy vs ATG 1.3 (0.83-2)  .3 
  No serotherapy vs Campath 0.91 (0.43-1.8)  .73 
Incidence of aGVHD grades III-IV    
 UCB vs MUD 4.2 (1-18) .357 .051 
 MSD vs MUD 1.4 (0.33-5.9) 1 .64 
 MSD vs UCB 0.33 (0.091-1.2) .658 .094 
 MSD vs dUCB 0.43 (0.12-1.6) 1 .22 
  Chemo-based vs TBI-based 1 (0.45-2)  .9 
  Age at HCT (spline 1) 0.91 (0.79-1.1)  .21 
  Age at HCT (spline 2) 1.1 (0.93-1.3)  .27 
  CSA/MMF vs CSA/Mtx 1.1 (0.31-3.8)  .88 
  CSA/MMF vs CSA/steroids 2 (0.83-5)  .13 
  No serotherapy vs ATG 1.1 (0.53-2.3)  .8 
  No serotherapy vs Campath 0.91 (0.19-4.2)  .88 
Incidence of cGVHD    
 UCB vs MUD 0.3 (0.14-0.67) .0217 .0031 
 MSD vs MUD 0.5 (0.21-1.1) .672 .096 
 MSD vs UCB 1.6 (0.62-4.2) 1 .3 
 MSD vs dUCB 1.5 (0.59-3.8) 1 .41 
  Chemo-based vs TBI-based 0.43 (0.24-0.83)  .0076 
  Age at HCT (spline 1) 1.1 (0.93-1.2)  .4 
  Age at HCT (spline 2) 0.9 (0.78-1)  .17 
  CSA/MMF vs CSA/Mtx 2.1 (1.1-4.3)  .032 
  CSA/MMF vs CSA/steroids 3.6 (0.83-16)  .093 
  No serotherapy vs ATG 1.1 (0.53-2.5)  .75 
  No serotherapy vs Campath 1 (0.42-2.3)  .94 
cGVHD-LFS    
 UCB vs MUD 0.56 (0.34-1) .033 .033 
 MSD vs MUD 0.67 (0.4-1) .073 .073 
 MSD vs UCB 1.1 (0.67-2) .65 .65 
 MSD vs dUCB 1 (0.56-1.8) .95 .95 
  Chemo-based vs TBI-based 0.83 (0.59-1.2)  .37 
  Age at HCT (spline 1) 0.95 (0.88-1)  .16 
  Age at HCT (spline 2) 1 (0.95-1.1)  .41 
  CSA/MMF vs CSA/Mtx 1.7 (1.1-2.8)  .025 
  CSA/MMF vs CSA/steroids 1.5 (0.91-2.6)  .14 

ATG, antithymocyte globulin.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal